iOnctura is developing a portfolio of precision oral small molecules that target cancers in novel ways. The Company has progressed two therapeutic candidates into mid-stage clinical development. The financing will be used to accelerate development of the lead asset for the treatment of uveal melanoma (UM), a rare cancer of the eye with few available treatments.
